Phosphatase Dysregulation in Cancer: Signaling Pathways and Therapeutic Opportunities

ABSTRACT Phosphatases are increasingly recognized as critical regulators of cancer biology, with important roles in both tumor cells and the tumor immune microenvironment (TIME). These enzymes modulate intracellular signaling pathways that control tumor growth, immune evasion, and metastasis. Althou...

Full description

Saved in:
Bibliographic Details
Main Authors: Maryam Jama, Michael Overduin, Khaled H. Barakat
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:MedComm – Oncology
Subjects:
Online Access:https://doi.org/10.1002/mog2.70028
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849434897946509312
author Maryam Jama
Michael Overduin
Khaled H. Barakat
author_facet Maryam Jama
Michael Overduin
Khaled H. Barakat
author_sort Maryam Jama
collection DOAJ
description ABSTRACT Phosphatases are increasingly recognized as critical regulators of cancer biology, with important roles in both tumor cells and the tumor immune microenvironment (TIME). These enzymes modulate intracellular signaling pathways that control tumor growth, immune evasion, and metastasis. Although phosphatases were once considered undruggable, recent advances have highlighted their therapeutic potential. Despite growing evidence, phosphatases remain underexplored as drug targets, with no approved therapies to date. This review presents an in‐depth overview of phosphatase classification based on catalytic domain similarities and explores their diverse functions as tumor suppressors, oncogenic drivers, or context‐dependent regulators. We describe how phosphatases such as PTPN6, PTPN22, and DUSPs regulate key pathways like RAS/MAPK and PI3K/AKT in both tumor and immune cells. Additionally, we discuss the role of phosphatases in shaping the tumor microenvironment through exosome secretion. This review highlights current therapeutic strategies, including small molecules and antibodies, and their synergistic effects with kinase inhibitors and immune checkpoint blockade. By summarizing recent advances, this paper underscores the need for deeper mechanistic insights into phosphatase function in cancer and immunity. Understanding these mechanisms will be key to unlocking their potential as novel therapeutic targets in oncology.
format Article
id doaj-art-ae32a48ea2874ce39cd1fad01d24331d
institution Kabale University
issn 2769-6448
language English
publishDate 2025-06-01
publisher Wiley
record_format Article
series MedComm – Oncology
spelling doaj-art-ae32a48ea2874ce39cd1fad01d24331d2025-08-20T03:26:29ZengWileyMedComm – Oncology2769-64482025-06-0142n/an/a10.1002/mog2.70028Phosphatase Dysregulation in Cancer: Signaling Pathways and Therapeutic OpportunitiesMaryam Jama0Michael Overduin1Khaled H. Barakat2Faculty of Pharmacy and Pharmaceutical Sciences University of Alberta Edmonton Alberta CanadaDepartment of Biochemistry, Faculty of Medicine and Dentistry University of Alberta Edmonton Alberta CanadaFaculty of Pharmacy and Pharmaceutical Sciences University of Alberta Edmonton Alberta CanadaABSTRACT Phosphatases are increasingly recognized as critical regulators of cancer biology, with important roles in both tumor cells and the tumor immune microenvironment (TIME). These enzymes modulate intracellular signaling pathways that control tumor growth, immune evasion, and metastasis. Although phosphatases were once considered undruggable, recent advances have highlighted their therapeutic potential. Despite growing evidence, phosphatases remain underexplored as drug targets, with no approved therapies to date. This review presents an in‐depth overview of phosphatase classification based on catalytic domain similarities and explores their diverse functions as tumor suppressors, oncogenic drivers, or context‐dependent regulators. We describe how phosphatases such as PTPN6, PTPN22, and DUSPs regulate key pathways like RAS/MAPK and PI3K/AKT in both tumor and immune cells. Additionally, we discuss the role of phosphatases in shaping the tumor microenvironment through exosome secretion. This review highlights current therapeutic strategies, including small molecules and antibodies, and their synergistic effects with kinase inhibitors and immune checkpoint blockade. By summarizing recent advances, this paper underscores the need for deeper mechanistic insights into phosphatase function in cancer and immunity. Understanding these mechanisms will be key to unlocking their potential as novel therapeutic targets in oncology.https://doi.org/10.1002/mog2.70028non‐receptor protein tyrosine phosphatasessignal transductiontherapeuticstumor microenvironmenttumor promotertumor suppressor
spellingShingle Maryam Jama
Michael Overduin
Khaled H. Barakat
Phosphatase Dysregulation in Cancer: Signaling Pathways and Therapeutic Opportunities
MedComm – Oncology
non‐receptor protein tyrosine phosphatases
signal transduction
therapeutics
tumor microenvironment
tumor promoter
tumor suppressor
title Phosphatase Dysregulation in Cancer: Signaling Pathways and Therapeutic Opportunities
title_full Phosphatase Dysregulation in Cancer: Signaling Pathways and Therapeutic Opportunities
title_fullStr Phosphatase Dysregulation in Cancer: Signaling Pathways and Therapeutic Opportunities
title_full_unstemmed Phosphatase Dysregulation in Cancer: Signaling Pathways and Therapeutic Opportunities
title_short Phosphatase Dysregulation in Cancer: Signaling Pathways and Therapeutic Opportunities
title_sort phosphatase dysregulation in cancer signaling pathways and therapeutic opportunities
topic non‐receptor protein tyrosine phosphatases
signal transduction
therapeutics
tumor microenvironment
tumor promoter
tumor suppressor
url https://doi.org/10.1002/mog2.70028
work_keys_str_mv AT maryamjama phosphatasedysregulationincancersignalingpathwaysandtherapeuticopportunities
AT michaeloverduin phosphatasedysregulationincancersignalingpathwaysandtherapeuticopportunities
AT khaledhbarakat phosphatasedysregulationincancersignalingpathwaysandtherapeuticopportunities